
WHAT IS CLAIMED IS:

1. A compound of formula (I), or its pharmaceutical acceptable salt,



(I)

wherein, R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22} and R^{23} independently from each other are H or D, and at least one of R^6, R^7, R^8 and R^9 is D.

2. The compound or its pharmaceutical acceptable salt of claim 1, wherein at least two, three or four of R^6, R^7, R^8 and R^9 is D. optionally no more than two, three or four of R^6, R^7, R^8 and R^9 is D, optionally all of R^1, R^2, R^3, R^4, R^5, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22} and R^{23} are H.

3. The compound or its pharmaceutical acceptable salt of claim 1, wherein no more than one of R^6, R^7, R^8 and R^9 is D, optionally all of R^1, R^2, R^3, R^4, R^5, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22} and R^{23} are H.

4. The compound or its pharmaceutical acceptable salt of claim 1, wherein one or two of R^6 or R^7 is D, optionally all of R^1, R^2, R^3, R^4, R^5, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22} and R^{23} are H.

5. The compound or its pharmaceutical acceptable salt of claim 1, wherein one or two of R^8 or R^9 is D, optionally all of R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22} and R^{23} are H.

6. The compound or its pharmaceutical acceptable salt of claim 1, wherein at least one, two, three, four or five of R^1, R^2, R^3, R^4 and R^5 is D, preferably at least one, two, three, four or five of R^1, R^2, R^3, R^4 and R^5 is D and at least one or two of R^8 and R^9 is D, more preferably at least one or two of R^1 and R^5 is D and at least one or two of R^8 and R^9 is D.

7. The compound or its pharmaceutical acceptable salt of claim 1, wherein at least one, two or three of R^{12}, R^{13} and R^{14} is D, optionally no more than one, two or three of R^{12}, R^{13} and R^{14} is D, preferably at least one or two of R^{12} and R^{13} is D and R^{14} is D.


8. The compound or its pharmaceutical acceptable salt of claim 1, wherein at least one, two or three of R^{16}, R^{17} and R^{18} is D, optionally no more than one, two or three of R^{16}, R^{17} and R^{18} is D.

9. The compound or its pharmaceutical acceptable salt of claim 1, wherein no more than one, two, three, four, five, six, seven, eight, nine, ten, eleven or twelve of R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{16}, R^{17} and R^{18} is D, optionally all of, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{19}, R^{20}, R^{21},

R^{22} and R^{23} are H.

10. The compound or its pharmaceutical acceptable salt of claim 1, wherein at least one or two of R^8 and R^9 is D and at least one, two or three of R^{16}, R^{17} and R^{18} is D; or at least one, two, three, four or five of R^1, R^2, R^3, R^4, and R^5 is D and at least one, two or three of R^{16}, R^{17} and R^{18} is D.

11. A compound of formula (Ia), or its pharmaceutical acceptable salt,




(Ia)

wherein, $R^{6'}$, $R^{7'}$, $R^{8'}$ and $R^{9'}$ independently from each other are H or D, wherein at least one, two, three or four of $R^{6'}$, $R^{7'}$, $R^{8'}$ and $R^{9'}$ is D.


12. The compound or its pharmaceutical acceptable salt of claim 11, wherein both of $R^{6'}$ and $R^{7'}$ are H when at least one or two of $R^{8'}$ and $R^{9'}$ is D.

13. The compound or its pharmaceutical acceptable salt of claim 11, wherein both of $R^{8'}$ and $R^{9'}$ are H when at least one or two $R^{6'}$ and $R^{7'}$ of is D.


14. A compound selected from




1




2




3




4




5




6




7




8




9



10



11



12

, or its pharmaceutical acceptable salt.

15. The compound or its pharmaceutical acceptable salt of any one of claims 1-14, wherein deuterium enrichment is no less than 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98% or 99%, optionally no more than 99.9%, 99%, 98%, 97%, 96%, 95%, or 90%.

16. A pharmaceutical composition comprising a compound or its pharmaceutical acceptable salt of any one of claims 1-15 and a pharmaceutically acceptable carrier and/or adjuvant.

17. Use of a dual agonist of PPARα and PPARγ in the manufacture of a medicament for modulating (e.g., agonizing) PPARα and/or PPARγ, wherein the dual agonist of PPARα and PPARγ is deuterated Aleglitazar or its pharmaceutical acceptable salt, and the compound or its pharmaceutical acceptable salt of claim 1.

18. Use of a dual agonist of PPARα and PPARγ in the manufacture of a medicament for the treatment and/or prophylaxis of diseases which are modulated by PPARα and/or PPARγ agonists, wherein the dual agonist of PPARα and PPARγ is deuterated Aleglitazar or its pharmaceutical acceptable salt, and the compound or its pharmaceutical acceptable salt of claim 1, wherein the disease is diabetes, non-insulin dependent diabetes mellitus, elevated blood pressure, dyslipidemia, atherosclerotic diseases, metabolic syndrome, or diabetic nephropathy, or renal injury, preferably renal injury caused by ureteral obstruction or unilateral ureteral obstruction.

19. A method for modulating (e.g., improving) the specific *in vitro* agonistic activity of PPARα or PPARγ of a dual agonist of PPARα and PPARγ, comprising deuterating the dual agonist, wherein the dual agonist of PPARα and PPARγ is deuterated Aleglitazar or its pharmaceutical acceptable salt, and the compound or its pharmaceutical acceptable salt of claim 1.